Cite
Lopez-Bonet E, Buxó M, Cuyàs E, et al. Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. J Clin Med. 2019;8(12)doi: 10.3390/jcm8122180.
Lopez-Bonet, E., Buxó, M., Cuyàs, E., Pernas, S., Dorca, J., Álvarez, I., Martínez, S., Pérez-Garcia, J. M., Batista-López, N., Rodríguez-Sánchez, C. A., Amillano, K., Domínguez, S., Luque, M., Morilla, I., Stradella, A., Viñas, G., Cortés, J., Oliveras, G., Meléndez, C., Castillo, L., Verdura, S., Brunet, J., Joven, J., Garcia, M., Saidani, S., Martin-Castillo, B., & Menendez, J. A. (2019). Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. Journal of clinical medicine, 8(12), . https://doi.org/10.3390/jcm8122180
Lopez-Bonet, Eugeni, et al. "Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer." Journal of clinical medicine vol. 8,12 (2019). doi: https://doi.org/10.3390/jcm8122180
Lopez-Bonet E, Buxó M, Cuyàs E, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Oliveras G, Meléndez C, Castillo L, Verdura S, Brunet J, Joven J, Garcia M, Saidani S, Martin-Castillo B, Menendez JA. Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. J Clin Med. 2019 Dec 11;8(12). doi: 10.3390/jcm8122180. PMID: 31835708; PMCID: PMC6947627.
Copy
Download .nbib